Haemonetics Corp
SWB:HAZ

Watchlist Manager
Haemonetics Corp Logo
Haemonetics Corp
SWB:HAZ
Watchlist
Price: 72.5 EUR -2.68% Market Closed
Market Cap: 2.3B EUR
Have any thoughts about
Haemonetics Corp?
Write Note

Net Margin
Haemonetics Corp

9.1%
Current
8%
Average
2.2%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
9.1%
=
Net Income
123.8m
/
Revenue
1.4B

Net Margin Across Competitors

Country US
Market Cap 3.8B USD
Net Margin
9%
Country JP
Market Cap 6.8T JPY
Net Margin
24%
Country CH
Market Cap 37.6B CHF
Net Margin
12%
Country DK
Market Cap 179.6B DKK
Net Margin
19%
Country US
Market Cap 15.8B USD
Net Margin
11%
Country CN
Market Cap 51.4B CNY
Net Margin
42%
Country CA
Market Cap 6.3B USD
Net Margin
-8%
Country KR
Market Cap 9.1T KRW
Net Margin
-358%
Country US
Market Cap 6.2B USD
Net Margin
29%
Country UK
Market Cap 4.5B GBP
Net Margin
7%
Country US
Market Cap 5.7B USD
Net Margin
9%
No Stocks Found

Haemonetics Corp
Glance View

Market Cap
2.3B EUR
Industry
Health Care

In the realm of healthcare, Haemonetics Corp. operates as a pivotal player, bridging the gap between innovation and life-saving technology. Founded in 1971, the company has evolved to become a leader in blood management solutions, riding the wave of advanced medical technology to cater primarily to hospitals and blood collection centers. At its core, Haemonetics specializes in products and software designed to optimize the collection, processing, and surgical use of blood. Among its notable contributions are devices for blood component separation and coagulation management systems, which play a critical role in ensuring that patients around the world receive safe and effective blood therapy. Revenue streams for Haemonetics come from a diverse range of blood management systems and services. Their offerings are not limited to physical products; the company also provides comprehensive software solutions that help institutions maximize efficiencies and improve patient outcomes. With a keen focus on research and development, Haemonetics continuously innovates to meet the stringent demands of the modern healthcare landscape. Their business model thrives on a combination of direct sales, strategic partnerships, and service agreements with hospitals and blood banks, all while maintaining a strong commitment to quality and regulatory compliance. Through its strategic approach, Haemonetics not only fulfills an essential healthcare need but also crafts a sustainable financial pathway by redefining how blood and related products are managed globally.

HAZ Intrinsic Value
145.68 EUR
Undervaluation 50%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
9.1%
=
Net Income
123.8m
/
Revenue
1.4B
What is the Net Margin of Haemonetics Corp?

Based on Haemonetics Corp's most recent financial statements, the company has Net Margin of 9.1%.